Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Research and development	$ 3,771	$ 4,968	$ 11,455	$ 17,719
General and administrative	2,332	2,767	7,442	8,210
Change in fair value of contingent consideration	132	551	(110)	2,598
Total operating expenses	6,235	8,286	18,787	28,527
Operating loss	(6,235)	(8,286)	(18,787)	(28,527)
Other income
Change in fair value of warrants liabilities	2	112	31	369
Interest income	101	34	175	76
Total other income	103	146	206	445
Net loss	(6,132)	(8,140)	(18,581)	(28,082)
Other comprehensive loss
Foreign currency translation adjustment	(1)		(2)
Total comprehensive loss	$ (6,133)	$ (8,140)	$ (18,583)	$ (28,082)
Net loss per common share basic	$ (0.76)	$ (1.53)	$ (2.60)	$ (5.28)
Net loss per common share diluted	$ (0.76)	$ (1.53)	$ (2.60)	$ (5.28)
Weighted-average common shares outstanding used to calculate basic net loss per common share	8,093,033	5,319,405	7,156,344	5,316,320
Weighted-average common shares outstanding used to calculate diluted net loss per common share	8,093,033	5,319,405	7,156,344	5,316,320